{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:53:11Z","timestamp":1781506391745,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In the phase 3 OCTANS study, daratumumab plus bortezomib\/melphalan\/prednisone (D-VMP) significantly improved response rates and progression-free survival versus VMP alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma (NDMM). Understanding the impact of treatment on patient-reported outcomes (PROs) is of increasing interest. Here, we report on the impact of D-VMP and VMP on PROs in OCTANS. PROs were a secondary endpoint and were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire, administered at screening, every 3 months (Year 1), every 6 months thereafter (until disease progression), and 8 and 16 weeks post disease progression. Treatment effects were estimated using a mixed-effects model with repeated measures. Overall, 220 patients were randomized (D-VMP, <jats:italic>n<\/jats:italic>\u2009=\u2009146; VMP, <jats:italic>n<\/jats:italic>\u2009=\u200974). Compliance rates were 100% at baseline in both treatment groups and remained relatively high by Month 12 (D-VMP, 82.6%; VMP, 67.4%). Comparable improvements from baseline were generally observed between treatment groups across most PRO scores. Significant improvements were observed with D-VMP versus VMP in Global Health Status (GHS) score at 9 months (<jats:italic>p<\/jats:italic>\u2009=\u20090.0443) and in social functioning and nausea and vomiting symptom scores at 12 months (<jats:italic>p<\/jats:italic>\u2009=\u20090.0042 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0012, respectively). In summary, transplant-ineligible Asian patients with NDMM demonstrated improvements in PROs following treatment with D-VMP and VMP; however, greater improvements were observed in GHS, social functioning, and nausea and vomiting symptoms with D-VMP.<\/jats:p>","DOI":"10.1007\/s00277-025-06303-3","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:30:08Z","timestamp":1747978208000},"page":"2765-2776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study"],"prefix":"10.1007","volume":"104","author":[{"given":"Weijun","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canchan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"6303_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"key":"6303_CR2","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J van Lammerts","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, Voorhorst M, Gresnigt E, Wiegman L, Buijsse O, Andringa G, Overdijk MB, Doshi P, Sasser K, de Weers M, Parren PWHI (2014) Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 124:3474. https:\/\/doi.org\/10.1182\/blood.V124.21.3474.3474","journal-title":"Blood"},{"key":"6303_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311\u2013321. https:\/\/doi.org\/10.1080\/19420862.2015.1007813","journal-title":"MAbs"},{"key":"6303_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P (2016) The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor\u2013mediated cross-linking. J Immunol 197:807\u2013813. https:\/\/doi.org\/10.4049\/jimmunol.1501351","journal-title":"J Immunol"},{"key":"6303_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NWCJ, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384\u2013394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"key":"6303_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams III","year":"2019","unstructured":"Adams HC III, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk N, Sasser AK, Casneuf T (2019) High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A 95:279\u2013289. https:\/\/doi.org\/10.1002\/cyto.a.23693","journal-title":"Cytometry A"},{"key":"6303_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC III, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, Van der Borght K, Smets T, Foulk B, Nielsen KC, Rusbuldt J, Axel A, Lysaght A, Ceulemans H, Stevenaert F, Usmani SZ, Plesner T, Avet-Loiseau H, Nijhof I, Mutis T, Schecter JM, Chiu C, Bahlis NJ (2021) Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia 35:573\u2013584. https:\/\/doi.org\/10.1038\/s41375-020-0855-4","journal-title":"Leukemia"},{"key":"6303_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378:518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"key":"6303_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J (2023) Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clin Lymphoma Myeloma Leuk 23:446\u2013455.e444. https:\/\/doi.org\/10.1016\/j.clml.2023.02.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6303_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05958-8","author":"W Fu","year":"2024","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J (2024) Daratumumab, bortezomib, Melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study. Ann Hematol. Online ahead of print. https:\/\/doi.org\/10.1007\/s00277-024-05958-8","journal-title":"Ann Hematol Online ahead Print"},{"key":"6303_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1188\/21.ONF.151-160","volume":"48","author":"MR LeBlanc","year":"2021","unstructured":"LeBlanc MR, LeBlanc TW, Leak Bryant A, Pollak KI, Bailey DE, Smith SK (2021) A qualitative study of the experiences of living with multiple myeloma. Oncol Nurs Forum 48:151\u2013160. https:\/\/doi.org\/10.1188\/21.ONF.151-160","journal-title":"Oncol Nurs Forum"},{"key":"6303_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.20.01370","volume":"39","author":"A Perrot","year":"2021","unstructured":"Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K (2021) Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol 39:227\u2013237. https:\/\/doi.org\/10.1200\/JCO.20.01370","journal-title":"J Clin Oncol"},{"key":"6303_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1186\/s12885-021-08325-2","volume":"21","author":"S Knop","year":"2021","unstructured":"Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Jakubowiak A, Doyen C, Lucio P, Nagy Z, Usenko G, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Losava G, Fujisaki T, Garg M, Wang J, Wroblewski S, Kudva A, Gries KS, Fastenau J, San-Miguel J, Cavo M (2021) Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer 21:659. https:\/\/doi.org\/10.1186\/s12885-021-08325-2","journal-title":"BMC Cancer"},{"key":"6303_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ajh.27326","volume":"99","author":"R Silbermann","year":"2024","unstructured":"Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG (2024) Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: patient-reported outcomes from GRIFFIN. Am J Hematol 99:1257\u20131268. https:\/\/doi.org\/10.1002\/ajh.27326","journal-title":"Am J Hematol"},{"key":"6303_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"6303_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"6303_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S (2010) Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 96:5\u201321. https:\/\/doi.org\/10.1093\/bmb\/ldq033","journal-title":"Br Med Bull"},{"key":"6303_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","volume":"87","author":"AK Kvam","year":"2011","unstructured":"Kvam AK, Fayers PM, Wisloff F (2011) Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol 87:330\u2013337. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01665.x","journal-title":"Eur J Haematol"},{"key":"6303_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70. https:\/\/doi.org\/10.1186\/1477-7525-5-70","journal-title":"Health Qual Life Outcomes"},{"key":"6303_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M (2018) The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas 9:353\u2013367. https:\/\/doi.org\/10.2147\/PROM.S156279","journal-title":"Patient Relat Outcome Meas"},{"key":"6303_CR21","unstructured":"Tsai JH, Guo N (2024) Informed by patient data \u2013 observations from China releasing its first patient-reported outcomes (PROs) guidance. Accessed August 15, 2024 https:\/\/open-health-group.foleon.com\/ispor\/journal\/chinas-first-patient-reported-outcomes-pros-guidance"},{"key":"6303_CR22","unstructured":"Center for Drug Evaluation Guidelines for the Application of Patient-Reported Outcomes in Clinical Drug Development (Pilot) (2024) Accessed August 15, 2024 https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=8a900c1173e7aaf72ea3724796cebbeb"},{"key":"6303_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.clml.2022.08.002","volume":"22","author":"ARS Yusuf","year":"2022","unstructured":"Yusuf ARS, Heiling HM, Deal AM, Jensen CE, Mangieri NJ, Nyrop KA, Lichtman EI, Rubinstein SM, Grant SJ, Wood WA, Tuchman SA, Nakamura ZM (2022) Longitudinal analysis of patient-reported cognitive function in multiple myeloma. Clin Lymphoma Myeloma Leuk 22:920\u2013927. https:\/\/doi.org\/10.1016\/j.clml.2022.08.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6303_CR24","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","volume":"7","author":"M Roussel","year":"2020","unstructured":"Roussel M, Moreau P, Hebraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Wang J, Vanquickelberghe V, de Boer C, Kampfenkel T, Gries KS, Fastenau J, Sonneveld P (2020) Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol 7:e874\u2013e883. https:\/\/doi.org\/10.1016\/S2352-3026(20)30356-2","journal-title":"Lancet Haematol"},{"key":"6303_CR25","doi-asserted-by":"publisher","first-page":"e1429","DOI":"10.1002\/cnr2.1429","volume":"5","author":"H Ludwig","year":"2022","unstructured":"Ludwig H, Bailey AL, Marongiu A, Khela K, Milligan G, Carlson KB, Rider A, Seesaghur A (2022) Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice. Cancer Rep (Hoboken) 5:e1429. https:\/\/doi.org\/10.1002\/cnr2.1429","journal-title":"Cancer Rep (Hoboken)"},{"key":"6303_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416\u2013429. https:\/\/doi.org\/10.1111\/ejh.12790","journal-title":"Eur J Haematol"},{"key":"6303_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J 11:40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06303-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:49Z","timestamp":1749105469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06303-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6303"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06303-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, Good Clinical Practices, and abided by all applicable regulatory requirements. The study protocol and amendments were reviewed and approved by Independent Ethics Committees and Institutional Review Boards at each participating site, and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"R.C., R.L., X.C., and C.C. are employees of Johnson & Johnson and own stock or stock options. M.Z. is an employee of IQVIA, which was contracted by Johnson & Johnson for the presented analyses. J.W. served as a member of the board of directors or advisory committees at AbbVie. All other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}